In response to increased questions from licensees and the public regarding the appropriate clinical use of Cannabidiol (CBD) products, the Policy Committee of the Board will develop FAQs to address the most-raised questions and concerns. The Board has decided not to pursue a formal position statement on use of CBD products at this time.